Challenges in the Control and Elimination of Plasmodium vivax Malaria

Journal article

The human malaria parasite Plasmodium vivax imposes unique challenges to its control and elimination. Primary among those is the hypnozoite reservoir of infection in endemic communities. It is the dominant source of incident malaria and exceedingly difficult to attack due to both inability to diagnose latent carriers and the potentially life-threatening toxicity of primaquine in patients with an inborn deficiency of G6PD, the only therapeutic option against hypnozoites. Large segments of endemic populations are not eligible for primaquine, and alternative strategies for managing the threat of relapse in any group have not been optimized or validated. Association of risk of primaquine failure against latent P. vivax with impaired alleles of P450 2D6 exacerbates the substantial pool of primaquine ineligibles. Resistance to chloroquine against acute P. vivax malaria commonly occurs; alternative therapies like ACTs are effective but seldom evaluated as a partner drug to primaquine in the essential radical cure. Many of the Anopheles mosquito vector of P. vivax in South and Southeast Asia, where >90% of infections occur, thrive in a diversity of habitats and exhibit wide ranges of feeding and breeding behavior. This chapter explores many of these challenges and possible approaches in controlling and eliminating endemic vivax malaria.

Authors: Asih, P; Syafruddin, D; Baird, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: IntechOpen
• Journal: Towards Malaria Elimination: A Leap Forward
• Publication date: 2018-07-18
• Acceptance date: 2018-04-09
• DOI: 10.5772/intechopen.77082
• EISBN: 978-1-83881-413-7
• ISBN: 9781789235517
• Keywords: Plasmodium vivax; hypnozoites; SBTMR; control; latent malaria; species-sanitation; Anopheles mosquitoes; malaria; glucose-6-phosphtate dehydrogenase (G6PD)